Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China

Virology Journal

Volumn 12, Issue 1, 2015, Pages

  Huang, Weijuan ^a   Li, Xiyan ^a   Cheng, Yanhui ^a   Tan, Minju ^a   Guo, Junfeng ^a   Wei, Hejiang ^a   Zhao, Xiang ^a   Lan, Yu ^a   Xiao, Ning ^a   Wang, Zhao ^a   Wang, Dayan ^a   Shu, Yuelong ^a  

^a Chinese CDC   (China)

Author keywords

50 Inhibitory concentration; Antiviral resistant; Influenza A (H1N1) pdm09; Oseltamivir

Indexed keywords

HEMAGGLUTININ; OSELTAMIVIR; SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; H1N1 VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; NA PROTEIN, INFLUENZA A VIRUS; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CHINA; CONTROLLED STUDY; DRUG EFFECT; HEMAGGLUTININ GENE; IC50; INFLUENZA VIRUS A H1N1; MOLECULAR PHYLOGENY; NEURAMINIDASE GENE; NONHUMAN; SEQUENCE ANALYSIS; TREND STUDY; VIRUS DETECTION; VIRUS GENE; VIRUS ISOLATION; ADOLESCENT; ADULT; AGED; CHILD; DNA SEQUENCE; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; GENETICS; HUMAN; INFANT; INFLUENZA; INFLUENZA A VIRUS (H1N1); ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR GENETICS; PRESCHOOL CHILD; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CHINA; DRUG RESISTANCE, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS; YOUNG ADULT;

EID: 84934287307     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-015-0317-1     Document Type: Article

References (19)

1. Ling LM, Chow AL, Lye DC, Tan AS, Krishnan P, Cui L, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis. 2010;50:963-9.
2. Campbell CN, Mytton OT, McLean EM, Rutter PD, Pebody RG, Sachedina N, et al. Hospitalization in two waves of pandemic influenza A(H1N1) in England. Epidemiol Infect. 2010;139:1560-9.
3. Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res. 2014;110:31-41.
4. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827-35.
5. Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, et al. Characterization of a large cluster of influenza A(H1N1)pdm09 virus cross-resistant to oseltamivir and peramivir during the 2013/2014 influenza season in Japan. Antimicrob Agents Chemother. 2015;59:2607-17. pii:AAC.04836-14.
6. WHO/Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva. November 2011and June 2012. Wkly Epidemiol Rec (WER). 2012; 87: 369-374.
7. Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, et al. Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14. Emerg Infect Dis. 2015;21:136-41.
8. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 2012;206:148-57.
9. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328:1272-5.
10. Chutinimitkul S, Herfst S, Steel J, Lowen AC, Ye J, van Riel D, et al. Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol. 2010;84:11802-13.
11. Liu Y, Childs RA, Matrosovich T, Wharton S, Palma AS, Chai W, et al. Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol. 2010;84:12069-74.
12. Zhang Y, Zhang Q, Gao Y, He X, Kong H, Jiang Y, et al. Keymolecular factors in hemagglutinin and PB2 contribute to efficient transmission of the 2009 H1N1 pandemic influenza virus. J Virol. 2012;86:9666-74.
13. Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 2015;117:27-38.
14. Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, et al. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J Virol. 2012;86:121-7.
15. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog. 2014;10(4):e1004065.
16. Abed Y, Pizzorno A, Bouhy X, Rhéaume C, Boivin G. Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. J Virol. 2014;88:1652-8.
17. Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014;19:1.
18. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A(H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother. 2010;54:3671-7.
19. Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses. 2010;2:2269-89.